Tumor endothelial cells express high pentraxin 3 levels
- 14 November 2016
- journal article
- research article
- Published by Wiley in Pathology International
- Vol. 66 (12) , 687-694
Abstract
It has been described that tumor progression has many similarities to inflammation and wound healing in terms of the signaling processes involved. Among biological responses, angiogenesis, which is necessary for tumor progression and metastasis, is a common hallmark; therefore, tumor blood vessels have been considered as important therapeutic targets in anticancer therapy. We focused on pentraxin 3 (PTX3), which is a marker of cancer‐related inflammation, but we found no reports on its expression and function in tumor blood vessels. Here we showed that PTX3 is expressed in mouse and human tumor blood vessels based on immunohistochemical analysis. We found that PTX3 is upregulated in primary mouse and human tumor endothelial cells compared to normal endothelial cells. We also showed that PTX3 plays an important role in the proliferation of the tumor endothelial cells. These results suggest that PTX3 is an important target for antiangiogenic therapy.Keywords
This publication has 40 references indexed in Scilit:
- Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cellsBritish Journal of Cancer, 2012
- CXCR7: A novel tumor endothelial marker in renal cell carcinomaPathology International, 2012
- HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endotheliumBritish Journal of Cancer, 2011
- Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant TumorsThe American Journal of Pathology, 2009
- Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell LinesMolecular & Cellular Proteomics, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Inflammation and cancerNature, 2002
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971